Losartan Potassium Tablet, Film Coated
Product Images NDC 68071-5114

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68071-5114). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 5114 3)

Label for Losartan Potassium 25 mg tablets, film coated, oral use, containing 30 tablets per bottle. The label shows NuCare Pharmaceuticals, Inc. as the labeler and includes active ingredient details, tablet description, barcodes, storage instructions, and warnings about keeping out of reach of children.*

FDA Label Image

Losartanaddress1 (Losartanaddress1)

FDA Label Image

Losartanaddress2 (Losartanaddress2)

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line graph comparing the percentage of patients with primary endpoint events over a 60-month study period between atenolol and losartan potassium. The graph shows adjusted risk reduction for losartan potassium at 13%, with a p-value of 0.021, indicating statistical significance.*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line graph comparing the percentage of patients with fatal/non-fatal stroke over study months between Atenolol and Losartan potassium treatments. The x-axis represents study months (0 to 66), and the y-axis shows the percentage of patients. The graph indicates an adjusted risk reduction of 25% in stroke occurrence with Losartan potassium compared to Atenolol.*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

A forest plot showing primary endpoint events within demographic subgroups comparing Losartan Potassium and Atenolol. It displays event rates (%) and hazard ratios with 95% confidence intervals for primary composite outcomes and stroke (fatal/non-fatal), across age, gender, race, isolated systolic hypertension, diabetes, and history of cardiovascular disease subgroups.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

A line graph illustrating the percentage of patients with event over time in months up to 48 months, comparing Losartan Potassium and placebo groups. The graph indicates risk reduction and includes a p-value, showing a divergence between the Losartan Potassium and placebo event rates.*

FDA Label Image

Losartanstructure (Losartanstructure)

Chemical structure of Losartan Potassium showing its molecular arrangement with key functional groups and potassium ion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.